Valeant has announced that the FDA has accepted for review the New Drug Application (NDA) for retigabine, a neuronal potassium channel opener for the adjunctive treatment for adult epilepsy patients with partial-onset seizures. In Phase 3 epilepsy trials, retigabine reduced seizure rates compared to patients taking placebo.

For more information call (800) 556-1937 or visit www.valeant.com.